One-time preparation costs of $2.1 million.
Swiss pharmaceutical company Novartis AG received permission from the regulator for selling the worlds most expensive drug to treat spinal muscular atrophy in children under the age of two, reports the Chronicle.info with reference to the Correspondent
As stated in the message of the company, Management of quality control food and drug administration approved the use of disposable drug Zolgensma, which costs $2,125 million
For comparison, the cost of the second most expensive in the world of drug called Luxturna is $850 thousand.
Novartis will give insurance companies the ability to pay for the cost of the drug in equal installments over five years. The company also promises to partially reimburse spent on the drug amount in the case that it will be ineffective.
“Approval Zolgensma is proof of how much gene therapy can change the process of treatment life-threatening genetic diseases such as spinal muscular atrophy”, — said the head of Novartis You Narasimhan.
“We believe that Zolgensma will be able to give children and their families suffering from this devastating disease, a life full of opportunities,” — said in a statement.
In India, surgeons removed from a man’s stomach spoon, screwdriver and knife
Spinal muscular atrophy is a hereditary disease in which the dysfunction of nerve cells in the spinal cord, leading to progressive development of muscle weakness and atrophy.